An industry update: The latest developments in therapeutic delivery

Abstract

The present industry update covers the period 1-30 June 2017, with information sourced from company press releases, regulatory and patent agencies as well as scientific literature. The combination of drug and devices such as improved, safer injectables (see various market reports, companies Adamis and Baxter), patches (Microdermis) and (nano)carriers are moving increasingly from the R&D stage into clinical trials and toward the market. This addresses increased safety and effectiveness requirements, limiting physico-chemical properties of active ingredients, cost-effectiveness and patient comfort through ease of use. Further attention in the market is on local delivery methods (such as intraocular by Icon Bioscience, Glaukos) and the sheer infinite possibilities of nanotechnology such as LDL nanocarriers, microneedles and hydrogel cubes. Another 21st century key technology area is mobile applications (Vital Art and Science) and connected devices (SmartPill, Pop Test Devices) which are increasingly finding their way into the drug delivery field to enable, for example, closed loop monitoring of drug dosing in trials and of patients with their care providers. Not surprisingly companies are increasingly utilizing convergence to combine their diverse capabilities (Vetter Pharma/Microdermis, TXCell/Lentigen Technology).